Drug Research

Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis

March 29, 2017

NEW YORK–(BUSINESS WIRE)–Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon”) today announced preclinical data demonstrating the importance of the Rho-associated coiled-coil kinase (ROCK) signaling pathway in the pathogenesis of pulmonary fibrosis, supporting the therapeutic potential of ROCK inhibition to treat the disease. The data will be presented today as a poster at the 2017 Keystone Symposia on Injury, […]

Blaze Bioscience Announces Tumor Paint BLZ-100 Publication in International Journal of Toxicology

March 28, 2017

SEATTLE–(BUSINESS WIRE)–Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company dedicated to improving the lives of cancer patients, today announced the publication of a peer-reviewed manuscript in International Journal of Toxicology describing the nonclinical safety and pharmacokinetic (PK) profile of Tumor Paint BLZ-100 in animal models. The publication entitled “Nonclinical Profile of BLZ-100, a […]

Euclises Pharmaceuticals, Inc. to Present Preclinical Efficacy Results at American Association for Cancer Research

March 28, 2017

ST. LOUIS–(BUSINESS WIRE)–Euclises Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation therapies that prevent tumor immune evasion and kill cancer by disrupting the tumor microenvironment, is pleased to announce that its abstract has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., on April 3, 2017. “Combination of […]

Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program

March 28, 2017

Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today the selection of COM902 as the lead clinical antibody candidate for its CGEN-15137/TIGIT T cell checkpoint inhibitor program in immuno-oncology. COM902 follows COM701 into the Company’s preclinical development pipeline. COM701 is the Company’s lead therapeutic antibody targeting PVRIG, for which IND is anticipated later this […]

Recipharm names 2016 International Environmental Award winner

March 27, 2017

Recipharm has announced that its 2016 International Environmental Award has been presented to Alistair Boxall, Professor in environmental science at the University of York, for his research into the impact of chemical contaminants on the environment and human health. Spanning more than two decades, Professor Alistair Boxall’s research has led to an improved understanding of […]

Eurofins to invest millions in new UK facility

March 27, 2017

Eurofins Scientific (EUFI.PA), a world leader in bioanalytical testing, has announced plans to establish a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4 million investment. The announcement follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent […]

Six Ways to Improve Your Clinical Trial Budget

March 24, 2017

Smaller companies have unique needs in regards to clinical trials. Historically, vendors have approached the clinical trials industry with a “one size fits all” technology approach that is too big, expensive and cumbersome to maintain, or provides little actual value for what the company actually wants to solve. This white paper introduces a solution ideally suited for the […]

Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus (HPV)-Associated Cancers

March 23, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologic therapeutics engineered to selectively target and modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the selection of its lead candidate, Cue-101, which targets human papillomavirus (HPV)-associated cancers. The Company expects Cue-101 to enter the clinic in the first half of […]

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease Preclinical Proof-of-Concept Achieved, IND-Enabling Activities Underway

March 23, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Gaucher disease. This late-stage preclinical program becomes AVROBIO’s second therapy for lysosomal storage disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program. The program for Gaucher disease […]

New CDISC Data Standard Aids Development of Therapies for Ebola Virus

March 23, 2017

AUSTIN, Texas–(BUSINESS WIRE)–The Clinical Data Interchange Standards Consortium (CDISC) and the Infectious Diseases Data Observatory (IDDO) announce the availability of a new standard to assist in the collection, aggregation and analysis of Ebola virus disease (EVD) research data. This standard is for use in EVD trials, leading to potential treatments and public health surveillance for […]

Increasing Enrollment While Reducing Sites

March 23, 2017

After decades of delayed trial timelines, slow site setup and poor patient enrollment remain the top barriers to completing clinical studies on time and on budget. However, a new trial model has surfaced that flattens these obstacles and provides sponsors with the enrollment and budget certainty they need to more effectively plan for study launch […]

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

March 22, 2017

COSTA MESA, CA–(Marketwired – Mar 22, 2017) – NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company’s discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), […]

OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

March 22, 2017

SAN DIEGO, March 21, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled “Intratumoral Electroporation-mediated IL-12 Gene Therapy Can Enhance Tumor Immunogenicity” (Poster #2074), at the Keystone Symposia Conference, “Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology,” in Whistler, British Columbia, […]

NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® Aims to accelerate treatments and a cure for glomerular kidney diseases

March 21, 2017

KING OF PRUSSIA, Pa., March 21, 2017 /PRNewswire-USNewswire/ — With a goal of bringing more effective treatments for rare glomerular kidney diseases (including Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), IgA Nephropathy, and Membranous Nephropathy) to the market faster, NephCure Kidney International (NKI), in partnership with the University of Michigan (UM), has launched a […]

Lin BioScience Licenses Novel Therapeutic Program for Brain Cancer from the University of Sydney

March 21, 2017

SAN DIEGO, March 21, 2017 /PRNewswire/ — Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology, and cardiology, today announced an exclusive licensing agreement with the University of Sydney for a microtubule-targeting agent to treat brain cancers. The therapeutic candidate, LBS-002, is a small molecule that disrupts the division of cancer […]

Western IRB Establishes Single-IRB Solution to Help Institutions Comply with New Mandate for NIH-Funded Research

March 21, 2017

Western Institutional Review Board® (WIRB™), the world’s leading provider of ethical review of clinical research, announced today the launch of its WIRB NIH Single Review Solution™ (SRS) for NIH-funded multi-site research. As the long-standing leader in supporting IRB reviews among its 2,300 institution clients, WIRB has an extensive background in reviewing clinical trials funded by […]

The Pistoia Alliance Tackles Laboratory Safety with the Launch of the Chemical Safety Library Service

March 20, 2017

Collaborative database of previously inaccessible hazardous chemical reactions improves safety for scientists carrying out experiments in the lab  The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has today announced the launch of the Chemical Safety Library (CSL) Service, which allows hazardous reaction information to be […]

8th Annual Biologics Formulation Development and Drug Delivery Forum

March 20, 2017

8th Annual Biologics Formulation Development and Drug Delivery Forum 14-16 June 2017 Berlin, Germany This marcus evans forum will discuss key challenges in biologics development, confronting formulation scientists and assist them with a better experiment protocol to ensure quality processes, efficient methodology and minimise failure risks. The delegates will benefit from experienced case study and […]

ERT Receives Fifth Consecutive Award for Outstanding Customer Service

March 20, 2017

ERT Receives Fifth Consecutive Award for Outstanding Customer Service Commitment to Exceeding Expectations, Driving High Satisfaction   PHILADELPHIA – March 20, 2017 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has received Omega Management Group Corporation’s NorthFace ScoreBoard (NFSB) AwardSM for consistent delivery of […]

Envigo expands R&D capabilities in non-animal technologies to meet regulatory and market requirements for in vitro assays

March 16, 2017

Princeton, NJ, USA. March 15, 2017: Envigo announces that it will develop and internally validate five to seven ion channel In vitro tests for measuring cardiac risk potential – ahead of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of this year. These assays will form an integrated suite of tests […]

UroToday.com, Leading Urology Reference Site, Launches a New Clinical Trials Portal

March 16, 2017

The first registry focused exclusively on genitourinary malignancies and trials actively enrolling patients Truckee, CA–Digital Science Press Inc., the global leader of the digital aggregation and delivery of urologic disease and treatment content through UroToday.com, announced today the launch of a Clinical Trials Portal on their website. This new portal is a streamlined access point […]

Certara Launches Simcyp Access to Expand Simulator Availability

March 16, 2017

New licensing approach allows smaller organizations to gain access to top physiologically-based pharmacokinetic (PBPK) modeling and simulation platform on a rental basis Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced the launch of Simcyp® Access. This new cloud-based licensing approach provides trained […]

AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis

March 15, 2017

MISSION VIEJO, CA–(Marketwired – March 15, 2017) – TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE BLOOD CELLS, MACROPHAGES AND LYMPHOCYTES DETAILED RESULTS TO BE SUBMITTED FOR PUBLICATION Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced that […]

twoXAR Announces Preclinical Proof-of-Concept Data on Novel Liver Cancer Candidate

March 14, 2017

PALO ALTO, Calif.–(BUSINESS WIRE)–twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced that its candidate targeting hepatocellular carcinoma (HCC or Liver Cancer), TXR-311, has shown positive results in cell-based assays. TXR-311 is a molecule that twoXAR identified as having a high probability of being effective in treating HCC. Proof-of-concept studies were performed by The […]

Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition

March 10, 2017

GERMANTOWN, MD–(Marketwired – Mar 8, 2017) – Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today provided a business update from the Company’s CEO, Vered Caplan. The Company also reported that revenue for the fiscal year ending November 30, 2016 increased 115% to $6.4 […]

Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model

March 8, 2017

BOSTON–(BUSINESS WIRE)–Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company that is regenerating biological function by selective protein acetylation, today announced the publication of data demonstrating reversal of chemotherapy-induced peripheral neuropathy after treatment with HDAC6 inhibitors including ricolinostat in a preclinical model. The article, titled “HDAC6 Inhibition Effectively Reverses Chemotherapy-Induced Peripheral Neuropathy,” was published online in PAIN, […]

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

March 8, 2017

CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapies, today reported updated data showing increased levels of genome editing efficiency in vivo and durability results with its CRISPR/Cas9 technology, following a single administration. Using its lipid nanoparticle (LNP) technology, […]